The value of tumour marker kinetics in the management of patients with primary hepatocellular carcinoma.

Abstract

Serum alpha-fetoprotein (AFP) has been measured during chemotherapy of ten patients with hepatocellular carcinoma. Whenever the AFP concentration of a sample was lower than that of the previous sample the apparent half-life (AHL) of the protein was calculated. The biological half-life of AFP is 5 days so that values in excess of this were indicative of continuing or increased synthesis and secretion of AFP. The AHL for AFP provided a means of assessing efficacy of treatment. Increases in AHL generally predicted a rise in serum AFP and give advance warning of the need to change therapy.

Cite this paper

@article{Buamah1988TheVO, title={The value of tumour marker kinetics in the management of patients with primary hepatocellular carcinoma.}, author={Paul K. Buamah and Oliver James and Andrew W. Skillen and Al Harris}, journal={Journal of surgical oncology}, year={1988}, volume={37 3}, pages={161-4} }